Novartis CDR (NVS) Actualités

Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation

Novartis secures exclusive global rights across multiple biologic targets to Lindy Biosciences' microglassification technology Collaboration...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Form 144 - Report of proposed sale of securities

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in...

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting;...

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]